The SP should take a run to $25+ and during September from what I see. Going to $30 and beyond could happen again. Earlier, results were thought to come during September from the clinical trial assessing the potency and selectivity of INFI's Hsp90 inhibitor using retaspimycin hydrochloride in non-small cell lung cancer. This trial is designed to evaluate the safety and efficacy of docetaxel plus retaspimycinis when the patients are naive to docetaxel treatment and heavy smokers. The results are now expected in this 2nd half or 2013.